Steven Cohen's CTNM Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 759,227 shares of Contineum Therapeutics, Inc. (CTNM) worth $8.68 M, representing 0.01% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Steven Cohen has maintained this position in CTNM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 391,582 shares. Largest reduction occurred in Q3 2025, reducing 20,994 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Contineum Therapeutics (CTNM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Contineum Therapeutics (CTNM) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +391,582 | Add 106.51% | 759,227 | $11.43 |
| Q3 2025 | -20,994 | Reduce 5.40% | 367,645 | $11.75 |
| Q2 2025 | +388,639 | New Buy | 388,639 | $3.97 |
Steven Cohen's Contineum Therapeutics Investment FAQs
Steven Cohen first purchased Contineum Therapeutics, Inc. (CTNM) in Q2 2025, acquiring 388,639 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Contineum Therapeutics, Inc. (CTNM) for 3 quarters since Q2 2025.
Steven Cohen's largest addition to Contineum Therapeutics, Inc. (CTNM) was in Q4 2025, adding 759,227 shares worth $8.68 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 759,227 shares of Contineum Therapeutics, Inc. (CTNM), valued at approximately $8.68 M.
As of the Q4 2025 filing, Contineum Therapeutics, Inc. (CTNM) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Contineum Therapeutics, Inc. (CTNM) was 759,227 shares, as reported at the end of Q4 2025.